Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on September 2, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Item EX-99.1). Six-month revenue $29.3M versus $74.7M operating expenses, producing a $41.2M net loss.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Item EX-99.1
- Six-month revenue $29.3M versus $74.7M operating expenses, producing a $41.2M net loss
- $23.6M impairment charges and $19.7M credit losses signal substantial deterioration in royalty-asset valuations and expected collections
- Cash, equivalents, and restricted cash $150.6M, including $51.3M restricted, limiting freely deployable liquidity
- Long-term debt $89.0M plus $14.1M current maturities, with $6.2M interest expense creating ongoing cash obligations
- Revenue concentration risk: three partners generated 43%, 37%, and 16% of six-month income and revenues
Item EX-99.2 · Exhibit EX-99.2
- XOMA’s six-month financial statements show $29.3M revenue but a $41.2M net loss, indicating substantial earnings pressure
- $23.6M impairment charges and $19.7M credit losses drove operating expenses to $74.7M
- Liquidity remained significant at $150.6M cash, cash equivalents and restricted cash, supporting planned operations for at least one year
- $89.0M long-term debt plus $14.1M current maturities create ongoing financing obligations
- Revenue concentration is high: three partners contributed 43%, 37% and 16% of total income and revenues
Item EX-99.3 · Exhibit EX-99.3
- Merger completed July 14, 2026, combining Ligand with XOMA’s royalty portfolio and expanding exposure to royalty-based cash flows
- XOMA shareholders received $39.00 per share plus CVRs tied to 75% of net Janssen Litigation proceeds
- Estimated net purchase consideration $886.2M, including $833.5M cash consideration and $63.5M deferred award settlement
- Financing included $700M of convertible notes, increasing leverage and creating future dilution risk despite 0% coupon
- Pro forma revenue $146.3M and net income $17.9M for six months ended June 30, 2026, versus Ligand standalone revenue $115.4M and net income $35.2M
- Preliminary purchase accounting includes $142.4M goodwill and $97.6M acquired intangible assets, with material valuation and amortization uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.